Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

Biotechnology

Healthcare
$149.40 -2.22%

-$6.27 today

Market cap
$20.01B
Beta
0.27
P/E (TTM)
63.6
EPS (TTM)
$4.34
52W Low $273.11High $495.55

Volume 2.52M

Average 1.11M

ALNY Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Alnylam Pharmaceuticals, Inc.NASDAQ: ALNY

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q2 FY2026 selling, general & admin of $347.92M rose 7.6% year over year, behind the +22.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 7.9% from the prior quarter. Over 3 fiscal years it compounded at +16.3% a year.

Context

  • Selling, general & admin amounted to 32.6% of revenue in FY2025, down 10.8 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 21 analysts of $2.91B (+140.3%) for the fiscal year ending Dec 2026, a step up from the +24.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$347.92M+7.9% QoQ
Last fiscal yearDec 2025
$1.21B+24.1% YoY
LTMJun 2026
$1.32B+22.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.6%+137.5%+129.9 pp
1 year+24.1%+140.3%+116.2 pp
3-year CAGR+16.3%+50.4%+34.1 pp
5-year CAGR+33.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
1.21B USD
Year-over-year change
+24.1%
4-year CAGR
+18.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ALNY compares with its peers on the latest reported figures

  • ALNY's LTM Jun 2026 selling, general & admin of $1.32B is the highest of the 6 companies compared; the peer median is $157.94M.
  • Its year-over-year change of +22.1% is the 4th highest of 5, against a peer median of +44.4%.
  • Selling, general & admin amounts to 27.4% of revenue for ALNY, versus a peer median of 110.1%.
ALNY Competitors Peer median
Selling, General & Admin for ALNY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$1.32B +22.1%+16.3%27.4%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$584.98M +66.3%+37.9%61.0%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$201.04M +64.9%+30.5%44.6%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$157.94M +14.5%+9.9%239.0%
WVEWave Life Sciences Ltd.LTM Mar 2026$79.08M +23.9%+14.3%110.1%
SLNSilence Therapeutics plcLTM Mar 2026$23.59M —+2.2%2560.2%
Peer median (excluding ALNY) $157.94M+44.4%+14.3%110.1%

Competitors are the stored peer set for ALNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue844.29M1.04B1.83B2.25B3.71B
Cost of Revenue140.14M168.82M310.41M323.37M677.17M
Gross Profit704.14M868.6M1.52B1.92B3.04B
Gross Margin83.4%83.7%83.0%85.6%81.8%
Research & Development792.16M883.02M1B1.13B1.32B
Selling, General & Admin620.64M770.66M795.65M975.53M1.21B
Operating Expenses1.41B1.65B1.8B2.1B2.54B
Depreciation & Amortization47.57M44.47M54.05M56.67M55.66M
EBITDA(661.56M)(926.56M)(258.24M)(178.85M)631.44M
EBITDA Margin-78.4%-89.3%-14.1%-8.0%17.0%
Operating Income(708.65M)(785.07M)(282.18M)(176.89M)501.58M
Operating Margin-83.9%-75.7%-15.4%-7.9%13.5%
Interest Income1.58M24.81M95.56M121.99M111.47M
Interest Expense143.02M155.97M121.22M141.86M252.63M
Other Income / Expenses(143.49M)(341.92M)(151.34M)(200.49M)(178.43M)
Income Before Tax(852.14M)(1.13B)(433.52M)(377.38M)323.15M
Pre-Tax Margin-100.9%-108.6%-23.7%-16.8%8.7%
Income Tax Expense680K4.16M6.73M(99.22M)9.41M
Net Income(852.82M)(1.13B)(440.24M)(278.16M)313.75M
Net Margin-101.0%-109.0%-24.1%-12.4%8.4%
EPS (Basic)(7.20)(9.30)(3.52)(2.18)2.39
EPS (Diluted)(7.20)(9.30)(3.52)(2.18)2.33
Weighted Avg Shares118.45M121.69M124.91M127.65M131M
Weighted Avg Shares (Diluted)118.45M121.69M124.91M127.65M134.68M

Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

Intrinsic Alpha fair value

Locked

Current Price

$149.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.